<DOC>
	<DOCNO>NCT01063062</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter study evaluate safety tolerability efficacy reduce disease activity tocilizumab [ RoActemra/Actemra ] monotherapy combination methotrexate patient active moderate severe rheumatoid arthritis ( RA ) . Patients eligible participate study currently experience inadequate response stable dose non-biologic disease-modifying antirheumatic drug ( DMARD ) . Patients receive 8 mg/kg tocilizumab [ RoActemra/Actemra ] intravenous infusion every 4 week total 6 infusion . The anticipated time study treatment 24 week . The target sample size 50-200 patient .</brief_summary>
	<brief_title>A Study With Tocilizumab RoActemra/Actemra Monotherapy Combination With Methotrexate Patients With Rheumatoid Arthritis ( PICTURE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient ≥ 18 year age Moderate severe rheumatoid arthritis ( RA ) least 6 month ( defined Disease Activity Score ( DAS28 ) &gt; 3.2 screening ) Patients active RA 12 week treatment DMARDs Patients inadequate response stable dose nonbiologic DMARD Autoimmune disease RA . Patients interstitial pulmonary fibrosis able tolerate methotrexate ( MTX ) patient Sjögren 's Syndrome RA permit Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow enrollment Prior history current inflammatory joint disease RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>